Sanofi, Genentech and Celgene Lead the Way in Reputation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
68
Sanofi, Genentech and Celgene Lead the Way in Reputation Institute’s 2018 US Pharma RepTrak®, The Largest Study on Reputation of Pharmaceutical Brands in the US

Boston, MA, June 14, 2018 (GLOBE NEWSWIRE) -- Reputation Institute (RI), the world’s leading provider of reputation measurement, monitoring and management services, today announced the company’s annual US Pharma RepTrak® rankings. Based on more than 2,608 individual ratings of pharmaceutical companies during the first quarter of 2018, the survey quantifies the emotional bond stakeholders have with pharma companies in the US, and how these connections drive supportive behavior such as the willingness to purchase a company’s products, recommend the brand, invest in or work for a company.  

The top 10 companies in RI’s 2018 US Pharma RepTrak are:

1.      Sanofi [NYSE: SNY]

2.      Genentech

3.      Celgene [NASDAQ: CELG]

4.      AbbVie [NYSE: ABBV]

5.      Biogen [NASDAQ: BIIB]

6.      Bayer [ETR: BAYN]

7.      Gilead [NASDAQ: GILD]

8.      Allergan [NYSE: AGN]

9.      Novo Nordisk [NYSE: NVO]

10.    McKesson [NYSE: MCK]

Observations of Reputation Disruption in 2018

The 2018 US Pharma RepTrak results reveal that national and industry reputations are under stress, with pharmaceutical companies following the broader national trends with a -3.7 point decline in reputation score compared to 2017. There is a significant erosion of trust in the pharmaceutical industry, with scores in “Benefit of the Doubt” and “Trust to Do the Right Thing” declining by 13 percent and 14 percent respectively year-over-year. Negative media coverage of the industry is a strong contributor to the reputation decline.

Among industry challenges, low familiarity within the general public hurts the pharmaceutical industry’s ability to communicate with their stakeholders and convey what they are about and doing. Within the pharmaceutical industry, 62 percent are challenged by low familiarity within the public perceptions. Likewise, 60 percent of respondents are either unsure or unconvinced as to whether pharma companies are exhibiting good governance. Many pharmaceutical companies are succeeding in areas the public has less concern for – financial performance – and failing in areas the public values most – governance.

“The study results reveal an opportunity for pharmaceutical companies to improve their reputation and increase stakeholder support,” said Ivan Rocabado, Reputation Institute Vice President and Consulting Director for North America. “Increasing familiarity of the corporate brand of pharma companies among the general public ties directly to a lift in ‘Trust’ and ‘Benefit of the Doubt’ resulting in greater support.”

Insights from the study highlight many opportunities for improving reputation within the pharma industry. The study results reveal that the top companies with the best reputations and broadest stakeholder support are distinguishing themselves by driving high scores in ethical governance, openness and transparency, and supporting good causes.

“Companies can’t just focus on financial performance,” explains Meghan Burke, Reputation Institute Research Analyst. “In particular, pharmaceutical companies need to lead with ethics, prioritize governance, be authentic and seize their narrative to enhance their reputation.” 

Learn More and Get Your Company’s Pulse Score

On an annual basis, RI measures the reputation of thousands of companies using the RepTrak framework, including measures of the most highly regarded and familiar multinational companies in 15 countries including Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, the United Kingdom and the United States.

To access the full list of the most reputable companies in the US please visit:  https://www.reputationinstitute.com/us-pharma-reptrak-2018   To get your company’s 2018 score and learn how you can improve your ranking and grow your stakeholder support, just ask us at: https://www.reputationinstitute.com/about/Contact-Us

About Reputation Institute Reputation Institute powers the world’s most reputable companies. By tracking and analyzing stakeholder perceptions, we unleash the power of reputation intelligence to enable leaders to build better companies. Our RepTrak® model analyzes the reputations of companies and is best known as the Forbes-published RepTrak 100. Underlying the model is the RepTrak methodology, the global gold standard for measuring reputation. Learn more at: http://www.reputationinstitute.com

Karen Hopp Bazini Hopp for Reputation Institute 917-514-1723 karen@bazinihopp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Expats Delight in Culture and Culinary Wonders of Lanxi

Updated Category News Views 65

Discovering the Hidden Treasures of Lanxi Lanxi, a delightful city located in East China's Zhejiang province, stands out as a cultural landmark and a vibrant commercial center. Recently, a group of international visitors had the chance to delve into its rich history, traditional arts, and delicious cuisine during their stay. Engaging Cultural Experiences The adventure...

Continue Reading
JPMorgan Asset Management's Major Stake in OSB Group Plc

Updated Category News Views 116

Understanding Major Holdings in OSB Group Plc Major shareholding notifications are vital for investors and stakeholders as they shed light on the dynamics of ownership and influence within a company. Recently, JPMorgan Asset Management Holdings Inc. has crossed significant thresholds in its holding in OSB Group Plc, revealing important insights into its investment...

Continue Reading
Why Pfizer Is the Healthcare Stock You Should Invest In

Updated Category News Views 83

Understanding the Healthcare Investment Landscape When people think of income investments, they often overlook the healthcare sector due to its average standing in S&P 500 rankings related to dividend yields. Despite being the eighth-ranked sector, several healthcare stocks defy this norm by offering substantial dividends, making them compelling options for investors. In...

Continue Reading
Bruno Marc's Crafture Leather Collection: Elevate Your Style

Updated Category News Views 131

Introducing the Crafture Leather Collection by Bruno Marc A new era of men’s premium leather dress shoes has arrived with the launch of Bruno Marc's Crafture Leather Collection. This innovative lineup is tailored for comfort, style, and everyday wear, crafted without the luxury markup often seen in high-end footwear. By merging traditional elegance with modern...

Continue Reading
Innovative Cancer Research from RWJBarnabas Health Surfaces

Updated Category News Views 311

Significant Advances in Oncology Research by RWJBarnabas Health Clinicians and scientists from RWJBarnabas Health and Rutgers Cancer Institute are set to present significant findings at an upcoming major oncology event. This meeting serves as a platform for showcasing progressive research aimed at transforming cancer care. The extensive cancer research program highlights...

Continue Reading